Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Merck & Co. Inc. (NYSE:MRK) is not interested in pursuing deals "solely or primarily for the specific purpose of tax
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury